Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.8 SEK | -4.53% | +3.77% | -2.72% |
Jan. 15 | Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- The company is in a robust financial situation considering its net cash and margin position.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- With an expected P/E ratio at 37.5 and 20.83 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.72% | 65.24M | D | ||
-3.43% | 186B | C+ | ||
-2.56% | 107B | C | ||
-3.94% | 67.44B | A | ||
+3.12% | 50.03B | B- | ||
+16.10% | 47.81B | B- | ||
+4.79% | 41.03B | B+ | ||
+1.57% | 26.85B | B | ||
+2.70% | 25.82B | A- | ||
-0.31% | 25.01B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- PAX Stock
- Ratings Paxman AB